On Thursday, Baxter International Inc. BAX reported a first-quarter 2025 adjusted EPS of 62 cents, beating the management guidance of 47 to 50 cents and the Wall Street estimate of 48 cents.The medical device company reported sales of $2.63 billion. That’s up 5% year over year on both a reported and operational basis, beating the consensus of $2.59 billion.The management expected Q1 sales growth of 3%-4% on a reported basis and approximately 4% on an operational basis.Companywide top-line performance on bot ...

For the quarter ended March 2025, Baxter International (BAX) reported revenue of $2.63 billion, down 26.9% over the same period last year. EPS came in at $0.55, compared to $0.65 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $2.57 billion, representing a surprise of +2.09%. The company delivered an EPS surprise of +14.58%, with the consensus EPS estimate being $0.48.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- ...

Baxter International (BAX) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to Baxter International's First Quarter twenty twenty five Earnings Conference Call. Your lines will remain in a listen only mode until the question and answer segment of today's call. Please press star then zero on your touch tone phone. As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permis ...

2 USE OF NON-GAAP FINANCIAL MEASURES FIRST -QUARTER 2025 EARNINGS To supplement Baxter's consolidated financial statements presented on a U.S. GAAP basis, the company discloses certain non-GAAP financial measures. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States. Baxter International Inc. May 1, 2025 FORWARD-LOOKING STATEMENTS 1 This presentation includes forward-looking statements concerning the company's financial results (including ...

Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS FIRST-QUARTER 2025 RESULTS DEERFIELD, Ill., MAY 1, 2025 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2025. "Our solid performance in the first quarter of 2025 reflects the ongoing impact of our transformation journey," said Brent Shafer, chair and interim chief executive officer. "Baxter today is a more focused and agile organization, well positioned to drive enhanced value for patients, hea ...

Baxter International Inc. (BAX) is scheduled to release first-quarter 2025 results on May 1, before the opening bell. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by 11.54%. BAX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 5.92%. (Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.)Q1 EstimatesCurrently, the consensus estimate for revenues is pegged at $2.57 billion, indicating a decline of ...

Baxter International Inc. (BAX) recently introduced Voalte Linq , a lightweight, wearable badge powered by Scotty assistant, a voice-activated technology, at the 2025 HIMSS Global Healthcare Conference. Voalte Linq is the company’s latest innovation within connected care, providing health systems with an ecosystem that promotes full connectivity for care teams and their patients. The latest product introduction by Baxter is aimed at driving workflow automation for hospital settings and transforming how care ...

Research and Development - R&D expenditures were $590 million in 2024, $518 million in 2023, and $450 million in 2022, reflecting a focus on enhancing future growth through clinical differentiation [43]. - The company is working to create a more resilient supply chain and may consolidate R&D facilities as part of its new operating model [43]. Financial Performance and Challenges - The company faced challenges in recovering cost increases for raw materials and components due to contractual limits and market forces, negatively impacting profit margins in 2022 and 2023 [36]. - The company’s profit margins were adversely affected in Q4 2024 due to increased supply chain costs related to ongoing recovery efforts [36]. - The company’s ability to increase prices is constrained by global healthcare cost containment efforts, including price controls and competitive tenders [38]. Workforce and Talent - The company employs approximately 38,000 people globally, with 15,000 in the United States and 23,000 outside the United States, emphasizing the importance of talent in achieving strategic objectives [53]. Regulatory Environment - The company is subject to extensive regulation by government agencies, including the FDA and EMA, impacting the marketing and sale of its products [50]. Competitive Landscape - The company’s competitive advantages include a broad product offering and strong relationships with customers, but it faces substantial competition from both domestic and international healthcare companies [37]. - The company has purchasing agreements with major Group Purchasing Organizations (GPOs) in the U.S., which may limit price increases and create competition from other suppliers [33]. Corporate Governance and Transparency - The company provides free access to its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K on its website [56]. - Reports are also available via EDGAR through the SEC website, ensuring transparency and accessibility for stakeholders [56]. - Corporate Governance Guidelines and Code of Conduct are accessible on the company's website, promoting accountability and ethical standards [56]. - Stockholders can request printed materials, indicating the company's commitment to shareholder communication [56]. - The company incorporates market risk disclosures in its financial reporting, highlighting its awareness of financial instrument risks [374]. Corporate Responsibility - The company’s corporate responsibility strategy focuses on empowering patients, protecting the planet, and championing communities, with a commitment to report progress annually [48].

FOURTH-QUARTER 2024 EARNINGS Baxter International Inc. February 20, 2025 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements concerning the company's financial results (including the outlook for first-quarter and full-year 2025) and business development and regulatory activities. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking ...

Baxter International Inc. (BAX) reported fourth-quarter 2024 adjusted earnings per share (EPS) of 58 cents, which beat the Zacks Consensus Estimate of 52 cents by 11.5%. The bottom line declined 10.8% from the year-ago quarter’s level due to a surge in costs and expenses.On a GAAP basis, the company reported a loss per share of 95 cents against EPS of 43 cents in the prior-year quarter. The significant loss was due to special items, primarily related to the impact of a Front Line Care goodwill impairment ch ...